HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G Manages Production Demands 'Day To Day' As Consumer Health Brands Drive Growth In Pandemic

Executive Summary

P&G reported personal health care brands drove overall health care organic sales up 9% to $2.26bn in its latest quarter. CFO Jon Moeller says consumer stockpiling caused production acceleration as its five largest North American plants in March increased production 22% over monthly average for previous year.

You may also be interested in...



After 5% Sales Growth In Its FY 2020, P&G Bullish For 2021 Despite Looming Economic Threats

Macro factors that could hamper results include the economic recession caused by businesses’ reactions to novel coronavirus pandemic, the impact of COVID-19 on consumer buying trends and disruptions to supply chains.

'Positive' Signs Abound For Perrigo, But 'Uncertainty' From Pandemic Complicates Outlook

"With all the positive things, I'd normally be raising guidance right now," says CEO Murray Kessler as Perrigo reports first-quarter results. But manufacturing operations aren't normal, and neither is the consumer health product marketplace.

C&D Boosts Gummy Vitamin Manufacturing As Consumer Stockpiling ‘Wiped Out’ Supply

Church & Dwight invests in two manufacturing plants to increase production of its vitafusion and L’il Critters gummies after COVID-19-related stockpiling clears many customers' inventories. Demand for the products and nasal hygiene helped drive 10.2% domestic consumer sales increase in the first quarter.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1125791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel